Usana Health Sciences (USNA) Current Deferred Revenue (2011 - 2022)

Usana Health Sciences (USNA) has 10 years of Current Deferred Revenue data on file, last reported at $19.6 million in Q1 2022.

• On a quarterly basis, Current Deferred Revenue rose 23.09% year-over-year to $19.6 million in Q1 2022; TTM through Jan 2022 was $19.6 million, a 23.09% increase from a year earlier, with the FY2022 full-year figure at $19.6 million, up 23.09% from the prior year.
• Current Deferred Revenue for Q1 2022 stood at $19.6 million, up from $16.0 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for USNA reached as high as $19.6 million in Q1 2022 and fell as low as $2.6 million in Q4 2018.
• Historically, Current Deferred Revenue has averaged $13.0 million across 4 years, with a median of $14.9 million in 2019.
• Across the five-year window, Current Deferred Revenue dropped 13.61% in 2018 and surged 423.51% in 2019, its largest moves.
• Year by year, Current Deferred Revenue stood at $2.6 million in 2018, then jumped by 423.51% to $13.9 million in 2019, then climbed by 15.16% to $16.0 million in 2021, then rose by 23.09% to $19.6 million in 2022.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $19.6 million in Q1 2022, $16.0 million in Q1 2021, and $13.9 million in Q4 2019.